| Renascor Resources Limited (RNU) ORDINARY FULLY PAID |
Materials |
$183 |
PSG Demonstration Facility Update
|
25 Aug 2025 9:32AM |
$0.066 |
$0.072 |
risen by
9.09%
|
|
RNU - Price-sensitive ASX Announcement
Full Release
Key Points
- Renascor Resources Limited is nearing completion of its PSG Demonstration Facility in South Australia.
- Mechanical and electrical installation works are in their final stages, with commissioning activities underway.
- The facility will produce battery-grade spherical graphite for lithium-ion battery anodes.
- Produced PSG will be used for customer qualification, product development, and supporting supply chain integration.
- The demonstration facility supports Renascor's vertically integrated Battery Anode Material strategy.
- Renascor leverages the Siviour Graphite Project in its operations.
- The update aligns with Australian Government critical minerals initiatives.
- Successful commissioning is expected to enable partnerships and offtake agreements with global battery and EV manufacturers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| XRF Scientific Limited (XRF) ORDINARY FULLY PAID |
Industrials |
$326 |
Cleansing Statement
|
25 Aug 2025 9:32AM |
$2.230 |
$2.290 |
risen by
2.69%
|
|
| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$169 |
Trading Halt
|
25 Aug 2025 9:32AM |
$1.580 |
$1.470 |
fallen by
6.96%
|
|
VTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Victory Metals Limited (VTM) requested a trading halt effective December 19, 2019.
- The trading halt is pending an announcement by the company.
- The halt was requested to maintain a fair and orderly market.
- Trading will resume on December 23, 2019, or upon release of the company's announcement.
- The Australian Securities Exchange (ASX) listed this request under Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GR Engineering Services Limited (GNG) ORDINARY FULLY PAID |
Materials |
$720 |
Full Year Statutory Accounts FY25
|
25 Aug 2025 9:31AM |
$4.410 |
$4.300 |
fallen by
2.49%
|
|
GNG - Price-sensitive ASX Announcement
Full Release
Key Points
- GR Engineering Services Limited released its Full Year Statutory Accounts for FY25.
- The report includes comprehensive financial statements: profit or loss, financial position, cash flows, and changes in equity.
- Significant accounting policies, revenue recognition, and financial management practices are discussed.
- The accounts provide information on key management remuneration and related party transactions.
- Operational highlights and major projects of the year are summarized.
- Risk management strategies and corporate governance practices are outlined.
- Income tax, expenses, and financial instruments are detailed with supporting notes.
- Critical accounting estimates, provisions, and contingencies are disclosed.
- Auditor’s independence and remuneration are reported.
- Segment reporting and detailed notes to the financial statements provide additional insights into company operations for FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Provaris Energy Ltd (PV1) ORDINARY FULLY PAID |
Energy |
$16 |
Trading Halt
|
25 Aug 2025 9:31AM |
$0.023 |
$0.020 |
fallen by
13.04%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$34 |
HERACLES clinical trial Update 3
|
25 Aug 2025 9:30AM |
$0.115 |
$0.115 |
fallen by
0%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- HERACLES is a Phase 1b/2 clinical trial evaluating SOFRA-001 in late-stage solid cancer patients.
- The trial aims to assess safety, tolerability, and initial efficacy of SOFRA-001.
- Early results suggest SOFRA-001 has a favorable safety profile, with no dose-limiting toxicities observed.
- Some patients have shown disease stabilization and tumor shrinkage.
- Recruitment and patient dosing are ongoing, with continued monitoring and data collection.
- Noxopharm Limited remains committed to developing SOFRA-001 as a new therapeutic option for advanced cancer patients.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Far Limited (FAR) ORDINARY FULLY PAID |
Energy |
$37 |
Half Year Report and Accounts
|
25 Aug 2025 9:30AM |
$0.390 |
$0.405 |
risen by
3.85%
|
|
FAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Covers the six-month period ended 31 December 2022.
- Focuses on Senegal and The Gambia exploration assets.
- Details operational progress, including license renewals and upcoming work commitments.
- Reports on financial position, cash flow, and expenditure control.
- Addresses corporate governance, including changes in board composition.
- Highlights ongoing risk management in light of market and operational uncertainties.
- Emphasises commitment to creating shareholder value and advancing exploration in West Africa.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Argent Biopharma Limited (RGT) ORDINARY FULLY PAID |
Health Care |
$10 |
U.S. In Vivo Study Supports ArtemiC Efficacy
|
25 Aug 2025 9:30AM |
$0.130 |
$0.145 |
risen by
11.54%
|
|
RGT - Price-sensitive ASX Announcement
Full Release
Key Points
- RGT and Argent Biopharma Limited announced positive results from a U.S.-based in vivo study on ArtemiC.
- The study demonstrates ArtemiC's efficacy in reducing disease symptoms and improving recovery in a preclinical COVID-19 animal model.
- ArtemiC is a novel oral spray formulation containing four active ingredients, including artemisinin and curcumin, aimed at reducing inflammation and mitigating cytokine storms.
- The in vivo study was conducted at a leading U.S. research institution using a validated COVID-19 animal model.
- Results showed statistically significant improvements in disease index, body weight, and survival rates in ArtemiC-treated animals compared to controls.
- No adverse reactions were observed in any of the treated animals throughout the study.
- The study supports the claimed anti-inflammatory and immune-modulatory effects of ArtemiC, aligning with previous clinical trial data from other regions.
- Regeneus and Argent Biopharma see these results as supporting further clinical development and commercialization efforts for ArtemiC in the U.S. and globally.
- The announcement affirms the companies' commitment to advancing novel therapies for diseases involving excessive inflammation, like COVID-19.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$968 |
1H25 Results Release
|
25 Aug 2025 9:29AM |
$3.020 |
$2.740 |
fallen by
9.27%
|
|
RPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Regal Partners Limited will release its 1H25 financial results on 14 August 2024.
- A results briefing will be held via live webcast at 10:00am (AEST) on the release date.
- Instructions for webcast registration are provided in the announcement.
- Results materials and investor presentation will be available on the ASX and Regal Partners website.
- Investor and media contact details are included for further inquiries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| XRF Scientific Limited (XRF) ORDINARY FULLY PAID |
Industrials |
$326 |
Application for quotation of securities - XRF
|
25 Aug 2025 9:29AM |
$2.230 |
$2.290 |
risen by
2.69%
|
|
| Qmines Limited (QML) ORDINARY FULLY PAID |
Materials |
$27 |
Strong Sulphides Intersected at Sulphide City
|
25 Aug 2025 9:29AM |
$0.054 |
$0.057 |
risen by
5.56%
|
|
QML - Price-sensitive ASX Announcement
Full Release
Key Points
- Qmines Limited (QML) reported strong sulphide intersections at Sulphide City, part of the Mt Chalmers Project.
- Recent drilling encountered significant copper, gold, silver, and zinc mineralisation.
- Mineralisation was intersected outside the current resource envelope, suggesting resource growth potential.
- All holes at Sulphide City intersected notable sulphide mineralisation, with some best-ever results.
- QML intends to conduct downhole geophysical surveys and further drilling to delineate mineralisation.
- The results highlight the prospectivity of Mt Chalmers for base and precious metals.
- The company’s exploration results support the progression towards development and eventual production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strategic Energy Resources Limited (SER) ORDINARY FULLY PAID |
Materials |
$4 |
Notice of Extraordinary General Meeting/Proxy Form
|
25 Aug 2025 9:29AM |
$0.005 |
$0.005 |
fallen by
0%
|
|
| Alligator Energy Limited (AGE) ORDINARY FULLY PAID |
Energy |
$102 |
Samphire Field Recovery Trial PEPR Approved
|
25 Aug 2025 9:28AM |
$0.022 |
$0.023 |
risen by
4.55%
|
|
AGE - Price-sensitive ASX Announcement
Full Release
Key Points
- AGE's Program for Environment Protection and Rehabilitation (PEPR) for the Samphire Field Recovery Trial (FRT) has been approved.
- Approval received from South Australian Department for Energy and Mining.
- Allows proceeding with an in-situ recovery (ISR) uranium extraction field recovery trial.
- Samphire Uranium Project is located near Whyalla, South Australia.
- Approval follows comprehensive baseline studies and regulatory engagement.
- Trial will collect technical, environmental, and operational data.
- Data will support future Mining Lease Application and potential project development.
- Trial aims to demonstrate safe and effective ISR uranium extraction.
- Represents a significant regulatory and project milestone for AGE.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Argent Minerals Limited (ARD) ORDINARY FULLY PAID |
Materials |
$33 |
Exploration Update over Kempfield Drilling Program
|
25 Aug 2025 9:28AM |
$0.020 |
$0.023 |
risen by
15%
|
|
ARD - Price-sensitive ASX Announcement
Full Release
Key Points
- Argent Minerals Limited has provided an exploration update for its Kempfield Drilling Program.
- The update focuses on the progress and objectives of the current diamond drilling campaign.
- Drilling targets high-grade polymetallic mineral zones containing silver, lead, zinc, and gold.
- Details are provided on the holes completed, planned drilling, and initial geological observations.
- Lithological and mineralization data from drilling are summarized with preliminary interpretations.
- The program aims to expand the Kempfield resource and improve understanding of the deposit.
- Assay results for recent drill holes are pending and will be reported in future updates.
- Argent Minerals remains committed to systematic exploration and resource growth at Kempfield.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,944 |
Notification of cessation of securities - NWS
|
25 Aug 2025 9:28AM |
$53.870 |
$53.170 |
fallen by
1.30%
|
|
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$968 |
Dividend/Distribution - RPL
|
25 Aug 2025 9:28AM |
$3.020 |
$2.740 |
fallen by
9.27%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,944 |
Notification of cessation of securities - NWS
|
25 Aug 2025 9:28AM |
$53.870 |
$53.170 |
fallen by
1.30%
|
|
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$968 |
Appendix 4D and Interim Financial Report, 6cps Dividend
|
25 Aug 2025 9:28AM |
$3.020 |
$2.740 |
fallen by
9.27%
|
|
RPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Regal Partners Limited released its Appendix 4D and Interim Financial Report for the half-year ended 30 June 2023.
- Statutory net profit after tax was $7.1 million; underlying net profit after tax was $13.0 million.
- A fully franked interim dividend of 6.0 cents per share was declared.
- The interim dividend has a record date of 31 August 2023 and will be paid on 14 September 2023.
- Fund growth was strong during the reporting period.
- RPL continued to invest in new strategies and platform developments.
- The successful acquisition of PM Capital Limited was completed.
- The report details financial performance, operational updates, risk management, and strategic direction.
- RPL is positioned for further growth and continued shareholder returns.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$17 |
Trading Halt
|
25 Aug 2025 9:27AM |
$0.071 |
$0.069 |
fallen by
2.82%
|
|
NIM - Price-sensitive ASX Announcement
Full Release
Key Points
- Nimy Resources Limited (NIM) requested a trading halt effective 17 June 2024.
- The trading halt relates to a pending announcement of a capital raising.
- Trading halt granted by ASX to ensure market is fully informed.
- The halt will remain until 19 June 2024 or until the announcement is made.
- The company is not aware of any reason the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EVT Limited (EVT) ORDINARY FULLY PAID |
Communication Services |
$2,314 |
Year End Results Presentation
|
25 Aug 2025 9:27AM |
$17.140 |
$14.240 |
fallen by
16.92%
|
|
EVT - Price-sensitive ASX Announcement
Full Release
Key Points
- EVT Limited reported year-on-year revenue and profit growth.
- Entertainment division benefited from strong movie releases and audience recovery.
- Hotels segment saw robust demand and revenue increases across key locations.
- Thredbo delivered record results, driven by strong visitor numbers and operational improvements.
- Strategic investments in technology and property supported business performance.
- Cost management and operational efficiencies contributed to improved margins.
- Expansion and renovation projects are planned to drive future growth.
- The company remains committed to sustainability and responsible business practices.
- Ongoing digital transformation aims to enhance customer experience and operational agility.
- Future strategy involves leveraging synergies between divisions and expanding market presence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$28 |
FY25 Results and Investor Briefing Details
|
25 Aug 2025 9:27AM |
$0.098 |
$0.098 |
fallen by
0%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,398 |
First site initiated for Neuren's PMS Phase 3 trial
|
25 Aug 2025 9:27AM |
$17.170 |
$19.000 |
risen by
10.66%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren Pharmaceuticals Limited initiated the Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome (PMS)
- First site for the SPRINT3 Phase 3 trial has been activated in the United States
- First participant screening for the trial has commenced
- The study will enroll approximately 90 children and adolescents with PMS across up to 15 US sites
- SPRINT3 is a randomized, double-blind, placebo-controlled trial with a 13-week treatment period followed by an open-label extension
- The primary endpoint will measure changes in the Aberrant Behavior Checklist-Community (ABC-C) total score
- NNZ-2591 previously demonstrated significant efficacy and a favorable safety profile in a Phase 2 trial
- The drug has received Orphan Drug and Rare Pediatric Disease designations from the FDA
- There are currently no approved therapies for PMS, addressing a significant unmet medical need
- Targeted completion of enrollment is in the first half of 2025 with results expected in the second half of 2025
- Neuren is also conducting a separate Phase 3 trial in Angelman syndrome and pursuing further neurodevelopmental disorder indications
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$14 |
Way2VAT Renews Key Financing Facility
|
25 Aug 2025 9:27AM |
$0.008 |
$0.008 |
fallen by
0%
|
|
| WAM Income Maximiser Limited (WMX) ORDINARY FULLY PAID |
Financials |
$164 |
Extraordinary General Meeting Chairman's Address
|
25 Aug 2025 9:26AM |
$1.650 |
$1.640 |
fallen by
0.61%
|
|
| Santos Limited (STO) ORDINARY FULLY PAID |
Energy |
$26,177 |
Santos 2025 Half-year Results
|
25 Aug 2025 9:26AM |
$7.760 |
$8.060 |
risen by
3.87%
|
|
STO - Price-sensitive ASX Announcement
Full Release
Key Points
- Santos Limited reported its 2025 Half-year Results, focusing on operational and financial performance.
- The company achieved strong production volumes and maintained disciplined capital management.
- Cost control and balance sheet strength were emphasized throughout the half-year period.
- Major project developments and progress on existing assets were highlighted.
- Santos continues to pursue sustainability initiatives, including decarbonisation and emissions reduction.
- Significant advancements in carbon capture and storage projects were reported.
- The company remains committed to delivering shareholder value and sustainable growth.
- Market conditions and the outlook for the second half of 2025 were discussed.
- Santos reaffirmed its strategy to achieve net-zero emissions targets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
